Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 5, 2012, Pages 637-643

  Abuirmeileh, Amjad ^a   Harkavyi, Alexander ^a   Rampersaud, Nazir ^a   Lever, Rebecca ^a   Tadross, John A ^b   Bloom, Stephen R ^b   Whitton, Peter S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

6 hydroxydopamine; dopamine release; exendin 4; L DOPA induced dyskinesias; Parkinson's disease

Indexed keywords

DOPAMINE; EXENDIN 4; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG DOSE COMPARISON; DYSKINESIA; EXTRACELLULAR SPACE; MALE; NONHUMAN; RAT;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; DYSKINESIAS; GLUCAGON-LIKE PEPTIDE 1; LEVODOPA; LIZARDS; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PEPTIDES; RATS; RATS, WISTAR; VENOMS;

EID: 84859575489     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01394.x     Document Type: Article

References (28)

1. Marsden CD, Parkes JD,. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet Neurol 1977; 1: 345-349.
2. Nutt J,. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990; 37: 340-345.
3. Calabresi P, et al,. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000; 47 (Suppl. 1): S60-S69.
4. Olanow CW, Obeso JA,. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000; 55 (Suppl. 1): 56-63.
5. Hauser RA,. Early pharmacologic treatment in Parkinson's disease. Am J Manag Care 2010; 16: 100-107.
6. Harkavyi A, et al,. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008; 5: 19.
7. Bertilsson G, et al,. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86: 326-338.
8. Li Y, et al,. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106: 1285-1290.
9. Lane EL, Dunnett SB,. Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav Brain Res 2010; 213: 66-72.
10. Abuirmeileh A, et al,. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. Eur J Neurosci 2007; 26: 417-423.
11. Biggs CS, et al,. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992; 59: 1702-1708.
12. Paxinos G, Watson C,. The Rat Brain in Stereotaxic Coordinates, 4th edn. New York: Academic Press, 1998.
13. Rascol O, et al,. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001; 16: 708-713.
14. Rajput AH, et al,. Clinical-pathological study of levodopa complications. Mov Disord 2002; 17: 289-296.
15. Choi-Lundberg DL, et al,. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-841.
16. Akerud P, et al,. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 2001; 21: 8108-8118.
17. Olanow CW, et al,. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677-687.
18. Vaillancourt DE, et al,. Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease. Brain 2004; 127: 491-504.
19. Vaillancourt DE, et al,. Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease. Mov Disord 2006; 21: 50-58.
20. Bensadoun JC, et al,. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 2000; 164: 15-24.
21. Barker RA,. Repairing the brain in Parkinson's disease: where next? Mov Disord 2002; 17: 233-241.
22. Gill SS, et al,. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-595.
23. Kastin AJ, Akerstrom V,. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes 2003; 27: 313-318.
24. Dethy S, et al,. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine. J Neural Transm 1999; 106: 145-158.
25. Kannari K, et al,. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J Neurochem 2000; 74: 263-269.
26. Jonkers N, et al,. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats. Eur J Pharmacol 2000; 407: 281-291.
27. Lee CH, et al,. Ischaemia-induced changes in glucagon-like peptide-1 and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischaemia. J Neurosci Res 2011; 89: 1103-1113.
28. Byetta Prescribing Information. Indianapolis N: Eli Lilly and Company. 2010. Available at.